Jundishapur Journal of Microbiology

Published by: Kowsar

Evaluation of Prognostic Values of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Crimean-Congo Hemorrhagic Fever Patients

Yunus Gurbuz 1 , Baris Ozturk 2 , * , Emin Ediz Tutuncu 1 , Irfan Sencan 1 , Gonul Cicek Senturk 1 and Fatma Aybala Altay 1
Authors Information
1 Infectious Diseases and Clinical Microbiology Clinics, Diskapi Yildirim Beyazit Training and Research Hospital, Ministry of Health, Ankara, Turkey
2 Infectious Diseases and Clinical Microbiology Clinics, Ulucanlar Training and Research Hospital, Ministry of Health, Ankara, Turkey
Article information
  • Jundishapur Journal of Microbiology: October 01, 2015, 8 (10); e26514
  • Published Online: October 20, 2015
  • Article Type: Research Article
  • Received: January 7, 2015
  • Revised: May 20, 2015
  • Accepted: July 7, 2015
  • DOI: 10.5812/jjm.26514

To Cite: Gurbuz Y, Ozturk B, Tutuncu E E, Sencan I, Cicek Senturk G, et al. Evaluation of Prognostic Values of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Crimean-Congo Hemorrhagic Fever Patients, Jundishapur J Microbiol. 2015 ; 8(10):e26514. doi: 10.5812/jjm.26514.

Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Ergonul O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, Esener H. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis. 2004; 39(2): 284-7[DOI][PubMed]
  • 2. Leblebicioglu H. Crimean-Congo haemorrhagic fever in Eurasia. Int J Antimicrob Agents. 2010; 36 Suppl 1-6[DOI][PubMed]
  • 3. Whitehouse C. Crimean?Congo hemorrhagic fever. Antiviral Res. 2004; 64(3): 145-60[DOI]
  • 4. Gunes T, Poyraz O, Vatansever Z. Crimean-Congo hemorrhagic fever virus in ticks collected from humans, livestock, and picnic sites in the hyperendemic region of Turkey. Vector Borne Zoonotic Dis. 2011; 11(10): 1411-6[DOI][PubMed]
  • 5. Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, Tasyaran MA, Vahaboglu H, et al. Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J Med Microbiol. 2005; 54: 385-9[DOI][PubMed]
  • 6. Ergönül Ö. Crimean-Congo haemorrhagic fever. Lancet Infect Dis. 2006; 6(4): 203-14[DOI]
  • 7. Akinci E, Bodur H, Leblebicioglu H. Pathogenesis of Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis. 2013; 13(7): 429-37[DOI][PubMed]
  • 8. Weber F, Mirazimi A. Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zonoosis. Cytokine Growth Factor Rev. 2008; 19(5-6): 395-404[DOI][PubMed]
  • 9. Ergonul O, Tuncbilek S, Baykam N, Celikbas A, Dokuzoguz B. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. J Infect Dis. 2006; 193(7): 941-4[DOI][PubMed]
  • 10. Papa A, Bino S, Velo E, Harxhi A, Kota M, Antoniadis A. Cytokine levels in Crimean-Congo hemorrhagic fever. J Clin Virol. 2006; 36(4): 272-6[DOI][PubMed]
  • 11. Ozturk B, Kuscu F, Tutuncu E, Sencan I, Gurbuz Y, Tuzun H. Evaluation of the association of serum levels of hyaluronic acid, sICAM-1, sVCAM-1, and VEGF-A with mortality and prognosis in patients with Crimean-Congo hemorrhagic fever. J Clin Virol. 2010; 47(2): 115-9[DOI][PubMed]
  • 12. Chuang YC, Lin YS, Liu CC, Liu HS, Liao SH, Shi MD, et al. Factors contributing to the disturbance of coagulation and fibrinolysis in dengue virus infection. J Formos Med Assoc. 2013; 112(1): 12-7[DOI][PubMed]
  • 13. Djamiatun K, Faradz SM, Setiati TE, Netea MG, van der Ven AJ, Dolmans WM. Increase of plasminogen activator inhibitor-1 and decrease of transforming growth factor-b1 in children with dengue haemorrhagic fever in Indonesia. J Trop Pediatr. 2011; 57(6): 424-32[DOI][PubMed]
  • 14. Rachman A, Rinaldi I. Coagulopathy in dengue infection and the role of interleukin-6. Acta Med Indones. 2006; 38(2): 105-8[PubMed]
  • 15. Yilmaz GR, Buzgan T, Irmak H, Safran A, Uzun R, Cevik MA, et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-2007. Int J Infect Dis. 2009; 13(3): 380-6[DOI][PubMed]
  • 16. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis. 1989; 11 Suppl 4-800[PubMed]
  • 17. Bakir M, Gozel MG, Koksal I, Asik Z, Gunal O, Yilmaz H, et al. Validation of a severity grading score (SGS) system for predicting the course of disease and mortality in patients with Crimean-Congo hemorrhagic fever (CCHF). Eur J Clin Microbiol Infect Dis. 2015; 34(2): 325-30[DOI][PubMed]
  • 18. Ergonul O, Celikbas A, Baykam N, Eren S, Dokuzoguz B. Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: severity criteria revisited. Clin Microbiol Infect. 2006; 12(6): 551-4[DOI][PubMed]
  • 19. Cevik MA, Erbay A, Bodur H, Gulderen E, Bastug A, Kubar A, et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis. 2008; 12(4): 374-9[DOI][PubMed]
  • 20. Tasdelen Fisgin N, Tanyel E, Doganci L, Tulek N. Risk factors for fatality in patients with Crimean-Congo haemorrhagic fever. Trop Doct. 2009; 39(3): 158-60[DOI][PubMed]
  • 21. Ozturk B, Tutuncu E, Kuscu F, Gurbuz Y, Sencan I, Tuzun H. Evaluation of factors predictive of the prognosis in Crimean-Congo hemorrhagic fever: new suggestions. Int J Infect Dis. 2012; 16(2)-93[DOI][PubMed]
  • 22. Jiang Z, Tang X, Xiao R, Jiang L, Chen X. Dengue virus regulates the expression of hemostasis-related molecules in human vein endothelial cells. J Infect. 2007; 55(2)-8[DOI][PubMed]
  • 23. Huang Y, Liu C, Wang S, Lei H, Liu H, Lin Y, et al. Activation of coagulation and fibrinolysis during dengue virus infection. J Med Virol. 2001; 63(3): 247-51[DOI]
  • 24. Shyu HW, Lin YY, Chen LC, Wang YF, Yeh TM, Su SJ, et al. The dengue virus envelope protein induced PAI-1 gene expression via MEK/ERK pathways. Thromb Haemost. 2010; 104(6): 1219-27[DOI][PubMed]
  • 25. Sosothikul D, Seksarn P, Pongsewalak S, Thisyakorn U, Lusher J. Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection. Thromb Haemost. 2007; [DOI]
  • 26. Wills BA, Oragui EE, Stephens AC, Daramola OA, Dung NM, Loan HT, et al. Coagulation abnormalities in dengue hemorrhagic Fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome. Clin Infect Dis. 2002; 35(3): 277-85[DOI][PubMed]
  • 27. Heller MV, Marta RF, Sturk A, Maiztegui JI, Hack CE, Cate JW, et al. Early markers of blood coagulation and fibrinolysis activation in Argentine hemorrhagic fever. Thromb Haemost. 1995; 73(3): 368-73[PubMed]
  • 28. Huang YH, Lei HY, Liu HS, Lin YS, Chen SH, Liu CC, et al. Tissue plasminogen activator induced by dengue virus infection of human endothelial cells. J Med Virol. 2003; 70(4): 610-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments